Actively Recruiting
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Led by M.D. Anderson Cancer Center · Updated on 2026-04-09
60
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to learn if a handheld Mass Spectrometry device called the MasSpec Pen can accurately identify malignant peripheral nerve sheath tumors (MPNST), neurofibroma, and normal nerve tissue during surgery. The study focuses on finding specific metabolic markers and validating the device's ability to help diagnose these conditions and assess surgical margins in real time. Participants with diagnosed MPNST or neurofibroma who are scheduled for surgical removal of these tumors as part of their usual care will be included. The study will analyze the metabolite and lipid profiles of the tumor and nerve tissues and test the handheld mass spectrometry device during surgery to evaluate its diagnostic accuracy and use in guiding surgical decisions. During the study, participants will undergo standard surgical procedures while researchers collect data using the device. Safety and any adverse events will be monitored throughout the study, which is expected to last about one year per participant. This observational study includes patients aged 1 year and older and will track how well the device performs in distinguishing tumor tissue during surgery.
CONDITIONS
Brief Title
DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with either malignant peripheral nerve sheath tumor (MPNST) or neurofibroma and scheduled for surgical removal as part of standard care
- Age 1 year or older; participants younger than 18 require consent from both parents
- Have at least one measurable lesion of 10 mm (1 cm) or larger by CT scan, MRI, or clinical exam
- Include both recurrent and primary disease cases
- Adults over 18 must understand and be willing to sign informed consent
- Open to English and non-English speaking patients
You will not qualify if you...
- Adults with cognitive impairments needing a legally authorized representative for consent
- Patients under 1 year old and newborns
- Pregnant patients undergoing surgery for MPNST
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to surgery date
Participants undergo metabolic profiling and diagnostic assessments using the handheld mass spectrometry device for tumor identification and surgical margin evaluation.
1 to 2 visits depending on surgical scheduling
Duration - Up to 1 week
Participants have surgical removal of the tumor as part of standard care with intraoperative evaluation using the mass spectrometry device.
1 surgical visit and immediate post-operative monitoring
Duration - Approximately 1 year
Participants are monitored for safety and adverse events for about one year after surgery.
Periodic follow-up visits during the monitoring period
Trial Site Locations
Total: 1 location
1
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77090
Actively Recruiting
Research Team
K
Keila Torres, MD,PHD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here